Literature DB >> 9616188

In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists.

B A Hamelin1, A Bouayad, B Drolet, A Gravel, J Turgeon.   

Abstract

Classic antihistamines, namely diphenhydramine, chlorpheniramine, clemastine, perphenazine, hydroxyzine, and tripelennamine, share structural features with substrates and inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6. Therefore, the current study was undertaken to characterize the in vitro inhibition of CYP2D6 by these commonly used, histamine H1 receptor antagonists. Microsomal incubations were performed using bufuralol as a specific CYP2D6 substrate and microsomes derived from human cells transfected with CYP2D6 cDNA. Reaction velocities were assessed in the absence and presence of antihistamines (20 microM) at 11 substrate concentrations (1, 2.5, 5, 7.5, 10, 15, 20, 25, 50, 75, and 100 microM), as well as at three nonsaturating substrate concentrations (2.5, 5, and 20 microM) and three inhibitor concentrations (5, 20, and 50 microM). In the presence of all antihistamines, the Vmax and KM of bufuralol 1'-hydroxylation were significantly altered, compared with the uninhibited reaction (p < 0.05). Lineweaver-Burke plots suggested competitive inhibition of the reaction by diphenhydramine and mixed inhibition by all other antihistamines tested. Diphenhydramine and chlorpheniramine, with estimated Ki values of approximately 11 microM, were the weakest inhibitors of CYP2D6 in vitro. Whereas tripelennamine, promethazine, and hydroxyzine were similar in their inhibitory capacities (Ki approximately 4-6 microM), clemastine appeared to be significantly more potent, with a Ki of approximately 2 microM. These data demonstrate that classic histamine H1 receptor antagonists, available in over-the-counter preparations, inhibit CYP2D6 in vitro. Furthermore, the CYP2D6-inhibitory concentrations of these antihistamines are in the range of their expected hepatic blood concentrations, suggesting that, under specific circumstances, clinically relevant interactions between classic antihistamines and CYP2D6 substrates might occur.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9616188

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  Drug-drug interactions: is there an optimal way to study them?

Authors:  L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

2.  Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.

Authors:  Michel Tod; Sylvain Goutelle; Fannie Clavel-Grabit; Grégoire Nicolas; Bruno Charpiat
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

Review 3.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Coprescription of tamoxifen and medications that inhibit CYP2D6.

Authors:  Kostandinos Sideras; James N Ingle; Matthew M Ames; Charles L Loprinzi; David P Mrazek; John L Black; Richard M Weinshilboum; John R Hawse; Thomas C Spelsberg; Matthew P Goetz
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

Review 5.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

6.  Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia.

Authors:  Junji Saruwatari; Masayuki Matsunaga; Kazuyuki Ikeda; Masashi Nakao; Kentaro Oniki; Takayuki Seo; Shuichi Mihara; Toru Marubayashi; Tetsuya Kamataki; Kazuko Nakagawa
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

7.  Abuse liability and stimulant properties of dextromethorphan and diphenhydramine combinations in rats.

Authors:  Jae H Jun; Eric B Thorndike; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

8.  Effects of terfenadine and diphenhydramine on the CYP2D6 activity in healthy volunteers.

Authors:  Selim Kortunay; Atila Bozkurt; Nursabah E Basci; S Oguz Kayaalp
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jul-Sep       Impact factor: 2.441

Review 9.  Sucralose, a synthetic organochlorine sweetener: overview of biological issues.

Authors:  Susan S Schiffman; Kristina I Rother
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2013       Impact factor: 6.393

10.  Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort.

Authors:  Tyren M Dodgen; Arinda Eloff; Connie Mataboge; Louw J L Roos; Werdie C W van Staden; Michael S Pepper
Journal:  Appl Transl Genom       Date:  2015-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.